ALFA Filings
Every announcement, straight from the exchange
Every Fredun Pharmaceuticals capital structure change announcement on NSE and BSE, newest first, each with its own page.
Time
7 announcements
Fredun Pharmaceuticals allotted 1,82,400 equity shares upon the conversion of 60,800 warrants. The company received total consideration of ₹7.60 Crore for this warrant conversion.
Fredun Pharmaceuticals has allotted 1,82,400 equity shares following the conversion of 60,800 warrants into equity shares, completing the preferential issue conversion process.
Fredun Pharmaceuticals allotted 3,61,599 equity shares following the conversion of 1,20,533 warrants. This allotment was executed at an issue price of Rs. 1,250 per warrant.
Fredun Pharmaceuticals allotted 1.10 crore bonus shares in a 2:1 ratio. Post-issue paid-up capital increased to Rs 16.54 crore from Rs 5.51 crore.
Fredun Pharmaceuticals Ltd promoters Fredun Nariman Medhora and others acquired 40,000 equity shares through the conversion of warrants on April 09, 2026. This conversion increases the total paid-up capital to 5,51,26,900 shares. The promoter group's voting rights increased from 44.17% to 44.57% following the allotment.
Fredun Pharmaceuticals Ltd allotted 40,000 equity shares to Director Daulat Nariman Medhora following the conversion of warrants. The transaction is valued at ₹5.0 Crore. This allotment increases the director's shareholding from 25.78% to 26.32%.
Fredun Pharmaceuticals Ltd allotted 40,000 equity shares to promoter Mrs. Daulat Nariman Medhora following the conversion of warrants. The transaction involved a balance payment of ₹3.75 Crore at an issue price of ₹1250 per share. This conversion completes the warrant exercise, resulting in nil warrants outstanding for this allottee.